Scientific papers

Please use the menu on the right to browse publications by year, cancer type or author, or enter a search term in the box below.

Displaying 1 - 10 of 18 papers
Click here to reset all search parameters [1]

Generalisability of pharmacoepidemiological studies using restricted prescription data [2]

Brown C, Barron T I, Bennett K, MacDonald D, Dwane F, Sharp L.

Ir J Med Sci. 2015 Oct 6. [Epub ahead of print].
Which women with breast cancer do, and do not, undergo receptor status testing? A population-based study [3]

de Camargo Cancela M, Comber H, Sharp L.

Cancer Epidemiol. 2015;39(5):778-82.
Understanding Women's Differing Experiences of Distress after Colposcopy: A Qualitative Interview Study [4]

O'Connor M, Waller J, Gallagher P, Martin CM, O'Leary J, D'Arcy T, Prendiville W, Flannelly G, Sharp L; Irish Screening Research Consortium (CERVIVA).

Womens Health Issues. 2015;25(5):528-34.
Interval cancer rates in the Irish national breast screening programme [5]

O’Brien, K. M., Dwane, F., Kelleher, T., Sharp, L., & Comber, H..

J Med Screen. 2015;22(3):136-43.
Psychometric evaluation of the EORTC QLQ-PR25 questionnaire in assessing health-related quality of life in prostate cancer survivors: a curate's egg [6]

O'Leary E, Drummond FJ, Gavin A, Kinnear H, Sharp L.

Qual Life Res. 2015;24(9):2219-30.
Patient reported "ever had" and "current" long term physical symptoms following prostate cancer treatments [7]

Gavin AT, Drummond FJ, Donnelly C, O'Leary E, Sharp L, Kinnear HR.

BJU Int. 2015;116(3):397-406.
Comparing the costs of three prostate cancer follow-up strategies: a cost minimisation analysis [8]

Pearce AM, Ryan F, Drummond F, Thomas AA, Timmons A, Sharp L..

Support Care Cancer. 2015;24(2):879-886.
Productivity losses associated with head and neck cancer using the Human Capital and Friction Cost approaches [9]

Pearce AM, Hanly P, Timmons A, Walsh PM, O'Neill C, O'Sullivan E, Gooberman-Hill R, Thomas AA, Gallagher P, Sharp L..

Appl Health Econ Health Policy. 2015;13(4):359-67.
Lottery ticket was more effective than a prize draw in increasing questionnaire response among cancer survivors [10]

Drummond FJ, O'Leary E, Sharp L.

J Clin Epidemiol. 2015;68(7):769-75.
De-novo post-diagnosis aspirin use and mortality in women with stage I-III breast cancer [11]

Barron TI, Murphy LM, Brown C, Bennett K, Visvanathan K, Sharp L.

Cancer Epidemiol Biomarkers Prev. 2015;24(6):898-904.

Pages

[13]

[14]